AGA2115

Phase 2Small molecule

AAngitia Incorporated Limited

AGA2115 is one of 23 small molecule programs targeting Osteogenesis Imperfecta. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteogenesis ImperfectaActive, not recruiting

Osteogenesis ImperfectaPhase 2

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Osteogenesis Imperfecta

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

7 2

Neoral

Novartis

Approved

—3

Aredia

HHikma Pharmaceuticals LLC

Approved

2 4

Fosamax

OOrganon and Co

Approved

2 5

Forteo

AAlmaject

Approved

2 6

Cytoxan

BBaxter Healthcare Corporation

Busulfex

Prolia

2 9

Risedronate Sodium

Sanofi

Phase 3

2 10

Genotropin

EMD Serono

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Osteogenesis Imperfecta

NCT07062588

Q3 2029

Phase 2Recruiting

Osteogenesis Imperfecta

NCT07557446

Clinical

Trials by Indication[1]

Osteogenesis Imperfecta2 trials

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)

Recruiting·AAngitia Incorporated Limited·Phase 2·NCT07062588·80 enrolled

A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta

Recruiting·AAngitia Biopharmaceuticals Guangzhou Limited·Phase 2·NCT07557446·48 enrolled

Adult1 trial

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

Completed·AAngitia Incorporated Limited·Phase 1·NCT06086613·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AGA2115. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AGA2115 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AGA2115. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Angitia Incorporated Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAngitia Incorporated Limited

AGA2115

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Trials by Indication[1]

Osteogenesis Imperfecta2 trials

Adult1 trial

References

Drug Info

Quick Facts

Related News